Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Buprenorphine buccal - BioDelivery Sciences International

Next Previous
Drug Profile

Buprenorphine buccal - BioDelivery Sciences International

Alternative Names: BELBUCA; BEMA Buprenorphine; BEMA® LA; BEMA® Long Acting; Buprenorphine long acting; Buprenorphine transmucosal; EN 3409

Latest Information Update: 10 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioDelivery Sciences International
  • Developer BioDelivery Sciences International; Purdue Biopharma
  • Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 03 Mar 2023 Aquestive Therapeutics reached an agreement with BioDelivery Sciences for the commercialisation of buprenorphine buccal and buprenorphine/naloxone transmucosal drug film products in the US
  • 22 Dec 2022 The Federal Circuit upholds judgment of the US district court for the District of Delaware regarding certain claims of patents protecting buprenorphine buccal
  • 22 Mar 2022 BioDelivery Sciences International has been acquired by Collegium Pharmaceutical
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top